

Treatment, Diagnosis and Differential Diagnosis of Cervical Squamous Cell Carcinoma
Abstract
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
Denny, L., Herrero, R., Levin, C., & Kim, J. J. (2015). Cervical cancer. In H. Gelband, P. Jha, R. Sankaranarayanan, & S. Horton (Eds.), Cancer: Disease control priorities (3rd ed., Vol. 3, pp. 421–435). The International Bank for Reconstruction and Development/The World Bank.
Herbert, A., Holdsworth, G., & Kubba, A. (2010). Why young women should be screened for cervical cancer: The distinction between CIN2 and CIN3. International Journal of Cancer, 126(9), 2256–2257. https://doi.org/10.1002/ijc.25194
Beavis, A. L., Gravitt, P. E., & Rositch, A. F. (2017). Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer, 123(6), 1044–1050. https://doi.org/10.1002/cncr.30376
Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7–30. https://doi.org/10.3322/caac.21590
Brambs, C. E., Höhn, A. K., Hentschel, B., Fischer, U., Bilek, K., & Horn, L. C. (2019). The prognostic impact of grading in FIGO IB and IIB squamous cell cervical carcinomas. Geburtshilfe und Frauenheilkunde, 79(2), 198–204. https://doi.org/10.1055/a-0831-0507
Schlichte, M. J., & Guidry, J. (2015). Current cervical carcinoma screening guidelines. Journal of Clinical Medicine, 4(5), 918–932. https://doi.org/10.3390/jcm4050918
Malone, C., Barnabas, R. V., Buist, D. S. M., Tiro, J. A., & Winer, R. L. (2020). Cost-effectiveness studies of HPV self-sampling: A systematic review. Preventive Medicine, 132, 105953. https://doi.org/10.1016/j.ypmed.2020.105953
Madzima, T. R., Vahabi, M., & Lofters, A. (2017). Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women: Focused literature review. Canadian Family Physician, 63(8), 597–601. https://pubmed.ncbi.nlm.nih.gov/28848489/
Petignat, P., Faltin, D. L., Bruchim, I., Tramèr, M. R., Franco, E. L., & Coutlée, F. (2007). Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecologic Oncology, 105(2), 530–535. https://doi.org/10.1016/j.ygyno.2007.02.006
Safaeian, M., Kiddugavu, M., Gravitt, P. E., Ssekasanvu, J., Murokora, D., Sklar, M., Serwadda, D., Wawer, M. J., Shah, K. V., & Gray, R. (2007). Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. Sexually Transmitted Diseases, 34(7), 429–436. https://doi.org/10.1097/01.olq.0000259117.22057.4f
Tropé, A., Sjøborg, K., Eskild, A., Cuschieri, K., Eriksen, T., Thoresen, S., Steinbakk, M., Laurak, V., Jonassen, C. M., Westerhagen, U., Jacobsen, M. B., Lie, A. K., & Jacobsen, M. B. (2009). Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. Journal of Clinical Microbiology, 47(8), 2458–2464. https://doi.org/10.1128/JCM.02112-08
Ting, J., Smith, J. S., & Myers, E. R. (2015). Cost-effectiveness of high-risk human papillomavirus testing with messenger RNA versus DNA under United States guidelines for cervical cancer screening. Journal of Lower Genital Tract Disease, 19(4), 333–339. https://doi.org/10.1097/LGT.0000000000000114
Cuzick, J., Sasieni, P., Davies, P., Adams, J., Normand, C., Frater, A., van Ballegooijen, M., & van den Akker-van Marle, E. (2000). A systematic review of the role of human papillomavirus (HPV) testing within a cervical screening programme: Summary and conclusions. British Journal of Cancer, 83(5), 561–565. https://doi.org/10.1054/bjoc.2000.1261
Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., Ghiringhello, B., Girlando, S., Gillio-Tos, A., De Marco, L., Naldoni, C., Pierotti, P., Rizzolo, R., Schincaglia, P., Zorzi, M., Zappa, M., Segnan, N., & Cuzick, J. (2010). Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncology, 11(3), 249–257. https://doi.org/10.1016/S1470-2045(09)70360-9
Leinonen, M. K., Nieminen, P., Lönnberg, S., Malila, N., Hakama, M., Pokhrel, A., Laurila, P., Tarkkanen, J., & Anttila, A. (2012). Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: Prospective randomised trial in Finland. BMJ, 345, e7789. https://doi.org/10.1136/bmj.e7789
Naucler, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., Rådberg, T., Strander, B., Johansson, B., Forslund, O., Hansson, B. G., Rylander, E., & Dillner, J. (2007). Human papillomavirus and Papanicolaou tests to screen for cervical cancer. New England Journal of Medicine, 357(16), 1589–1597. https://doi.org/10.1056/NEJMoa071430
Ogilvie, G. S., van Niekerk, D., Krajden, M., Smith, L. W., Cook, D., Gondara, L., Ceballos, K., Quinlan, D., Lee, M., Martin, R. E., Gentile, L., Peacock, S., Stuart, G. C. E., Franco, E. L., Coldman, A. J. (2018). Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: The HPV FOCAL randomized clinical trial. JAMA, 320(1), 43–52. https://doi.org/10.1001/jama.2018.7815
Thomsen, L. T., Kjær, S. K., Munk, C., Frederiksen, K., Ørnskov, D., Waldstrøm, M. (2020). Clinical performance of human papillomavirus (HPV) testing versus cytology for cervical cancer screening: Results of a large Danish implementation study. Clinical Epidemiology, 12, 203–213. https://doi.org/10.2147/CLEP.S297753
Melnikow, J., Henderson, J. T., Burda, B. U., Senger, C. A., Durbin, S., Weyrich, M. S. (2018). Screening for cervical cancer with high-risk human papillomavirus testing: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA, 320(7), 687–705. https://doi.org/10.1001/jama.2018.10840
Egemen, D., Cheung, L. C., Chen, X., Demarco, M., Perkins, R. B., Kinney, W., Poitras, N., Befano, B., Locke, A., Guido, R. S., Wiser, A. L., Gage, J. C., Katki, H. A., Wentzensen, N., Castle, P. E., Schiffman, M. (2020). Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines. Journal of Lower Genital Tract Disease, 24(2), 132–143. https://doi.org/10.1097/LGT.0000000000000515
Cheung, L. C., Egemen, D., Chen, X., Katki, H. A., Demarco, M., Wiser, A. L., Perkins, R. B., Guido, R. S., Wentzensen, N., Schiffman, M. (2020). 2019 ASCCP risk-based management consensus guidelines: Methods for risk estimation, recommended management, and validation. Journal of Lower Genital Tract Disease, 24(2), 90–101. https://doi.org/10.1097/LGT.0000000000000514
Lichter, K., Krause, D., Xu, J., Tsai, S. H. L., Hage, C., Weston, E., Eke, A., Levinson, K. (2020). Adjuvant human papillomavirus vaccine to reduce recurrent cervical dysplasia in unvaccinated women: A systematic review and meta-analysis. Obstetrics & Gynecology, 135(5), 1070–1083. https://doi.org/10.1097/AOG.0000000000003771
Mota, F. (2003). Microinvasive squamous carcinoma of the cervix: Treatment modalities. Acta Obstetricia et Gynecologica Scandinavica, 82(6), 505–509. https://doi.org/10.1034/j.1600-0412.2003.082006505.x
Hogness, C. G., Engelstad, L. P., Linck, L. M., & Schorr, K. A. (1992). Cervical cancer screening in an urban emergency department. Annals of Emergency Medicine, 21(8), 933–939. https://doi.org/10.1016/S0196-0644(05)80973-1
Refbacks
- There are currently no refbacks.